Neovasc Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVCN.TO research report →
Companywww.neovasc.com
Neovasc Inc. , a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina.
- CEO
- Fredericus A. Colen
- IPO
- 2014
- Employees
- 49
- HQ
- Richmond, BC, CA
Price Chart
Valuation
- Market Cap
- $110.78M
- P/E
- -1.99
- P/S
- 21.78
- P/B
- 5.18
- EV/EBITDA
- -1.89
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 79.66%
- Op Margin
- -886.75%
- Net Margin
- -1082.90%
- ROE
- -121.07%
- ROIC
- -116.83%
Growth & Income
- Revenue
- $3.81M · 49.37%
- Net Income
- $-41,204,418 · -65.55%
- EPS
- $0.00 · 100.00%
- Op Income
- $-33,740,809
- FCF YoY
- 8.41%
Performance & Tape
- 52W High
- $41.20
- 52W Low
- $6.00
- 50D MA
- $39.26
- 200D MA
- $19.32
- Beta
- 2.01
- Avg Volume
- 891
Get TickerSpark's AI analysis on NVCN.TO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our NVCN.TO Coverage
We haven't published any research on NVCN.TO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NVCN.TO Report →